These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 26854716)
21. A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers. Li BT; Drilon A; Johnson ML; Hsu M; Sima CS; McGinn C; Sugita H; Kris MG; Azzoli CG Ann Oncol; 2016 Jan; 27(1):154-9. PubMed ID: 26487589 [TBL] [Abstract][Full Text] [Related]
22. Cell-free DNA concentration and integrity as a screening tool for cancer. Zaher ER; Anwar MM; Kohail HM; El-Zoghby SM; Abo-El-Eneen MS Indian J Cancer; 2013; 50(3):175-83. PubMed ID: 24061455 [TBL] [Abstract][Full Text] [Related]
23. Combination of Circulating Cell-Free DNA and Positron Emission Tomography to Distinguish Non-Small Cell Lung Cancer from Tuberculosis. Zheng W; Quan B; Gao G; Zhang P; Huang L Lab Med; 2023 Mar; 54(2):130-141. PubMed ID: 36106407 [TBL] [Abstract][Full Text] [Related]
25. Quantification of free circulating DNA as a diagnostic marker in lung cancer. Sozzi G; Conte D; Leon M; Ciricione R; Roz L; Ratcliffe C; Roz E; Cirenei N; Bellomi M; Pelosi G; Pierotti MA; Pastorino U J Clin Oncol; 2003 Nov; 21(21):3902-8. PubMed ID: 14507943 [TBL] [Abstract][Full Text] [Related]
26. Optimization of circulating cell-free DNA recovery for KRAS mutation and HPV detection in plasma. Mazurek AM; Fiszer-Kierzkowska A; Rutkowski T; Składowski K; Pierzyna M; Scieglińska D; Woźniak G; Głowacki G; Kawczyński R; Małusecka E Cancer Biomark; 2013; 13(5):385-94. PubMed ID: 24440979 [TBL] [Abstract][Full Text] [Related]
27. Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules. Daly S; Rinewalt D; Fhied C; Basu S; Mahon B; Liptay MJ; Hong E; Chmielewski G; Yoder MA; Shah PN; Edell ES; Maldonado F; Bungum AO; Borgia JA J Thorac Oncol; 2013 Jan; 8(1):31-6. PubMed ID: 23201823 [TBL] [Abstract][Full Text] [Related]
28. Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer. Balgkouranidou I; Chimonidou M; Milaki G; Tsarouxa EG; Kakolyris S; Welch DR; Georgoulias V; Lianidou ES Br J Cancer; 2014 Apr; 110(8):2054-62. PubMed ID: 24642624 [TBL] [Abstract][Full Text] [Related]
29. Expression of miR-148/152 family as potential biomarkers in non-small-cell lung cancer. Li L; Chen YY; Li SQ; Huang C; Qin YZ Med Sci Monit; 2015 Apr; 21():1155-61. PubMed ID: 25904302 [TBL] [Abstract][Full Text] [Related]
30. Decreased expression of miR-204 in plasma is associated with a poor prognosis in patients with non-small cell lung cancer. Guo W; Zhang Y; Zhang Y; Shi Y; Xi J; Fan H; Xu S Int J Mol Med; 2015 Dec; 36(6):1720-6. PubMed ID: 26497897 [TBL] [Abstract][Full Text] [Related]
31. Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls. Xia S; Huang CC; Le M; Dittmar R; Du M; Yuan T; Guo Y; Wang Y; Wang X; Tsai S; Suster S; Mackinnon AC; Wang L Lung Cancer; 2015 Oct; 90(1):78-84. PubMed ID: 26233568 [TBL] [Abstract][Full Text] [Related]
32. Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer. Sirera R; Bremnes RM; Cabrera A; Jantus-Lewintre E; Sanmartín E; Blasco A; Del Pozo N; Rosell R; Guijarro R; Galbis J; Sánchez JJ; Camps C J Thorac Oncol; 2011 Feb; 6(2):286-90. PubMed ID: 21252717 [TBL] [Abstract][Full Text] [Related]
33. Clinical significance of circulating tumor cells and free DNA in non-small cell lung cancer. Isobe K; Hata Y; Kobayashi K; Hirota N; Sato K; Sano G; Sugino K; Sakamoto S; Takai Y; Shibuya K; Takagi K; Homma S Anticancer Res; 2012 Aug; 32(8):3339-44. PubMed ID: 22843912 [TBL] [Abstract][Full Text] [Related]
34. A Noninvasive Multianalytical Approach for Lung Cancer Diagnosis of Patients with Pulmonary Nodules. Liu QX; Zhou D; Han TC; Lu X; Hou B; Li MY; Yang GX; Li QY; Pei ZH; Hong YY; Zhang YX; Chen WZ; Zheng H; He J; Dai JG Adv Sci (Weinh); 2021 Jul; 8(13):2100104. PubMed ID: 34258160 [TBL] [Abstract][Full Text] [Related]
35. Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients. Paweletz CP; Sacher AG; Raymond CK; Alden RS; O'Connell A; Mach SL; Kuang Y; Gandhi L; Kirschmeier P; English JM; Lim LP; Jänne PA; Oxnard GR Clin Cancer Res; 2016 Feb; 22(4):915-22. PubMed ID: 26459174 [TBL] [Abstract][Full Text] [Related]
36. A prediction model based on DNA methylation biomarkers and radiological characteristics for identifying malignant from benign pulmonary nodules. Xing W; Sun H; Yan C; Zhao C; Wang D; Li M; Ma J BMC Cancer; 2021 Mar; 21(1):263. PubMed ID: 33691657 [TBL] [Abstract][Full Text] [Related]
37. Aberrant reduction of telomere repetitive sequences in plasma cell-free DNA for early breast cancer detection. Wu X; Tanaka H Oncotarget; 2015 Oct; 6(30):29795-807. PubMed ID: 26356673 [TBL] [Abstract][Full Text] [Related]
38. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Sozzi G; Conte D; Mariani L; Lo Vullo S; Roz L; Lombardo C; Pierotti MA; Tavecchio L Cancer Res; 2001 Jun; 61(12):4675-8. PubMed ID: 11406535 [TBL] [Abstract][Full Text] [Related]
39. 5-Hydroxymethylome in Circulating Cell-free DNA as A Potential Biomarker for Non-small-cell Lung Cancer. Zhang J; Han X; Gao C; Xing Y; Qi Z; Liu R; Wang Y; Zhang X; Yang YG; Li X; Sun B; Tian X Genomics Proteomics Bioinformatics; 2018 Jun; 16(3):187-199. PubMed ID: 30010036 [TBL] [Abstract][Full Text] [Related]
40. Coexisting pulmonary nodules in operable lung cancer: prevalence and probability of malignancy. Ruppert AM; Lerolle U; Carette MF; Lavole A; Khalil A; Bazelly B; Antoine M; Cadranel J; Milleron B Lung Cancer; 2011 Nov; 74(2):233-8. PubMed ID: 21511355 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]